BioLegend

BioLegend
Company type
Subsidiary
IndustryBiotechnology
Founded2002
Headquarters
San Diego, California
,
U.S.
Area served
Worldwide
Key people
Gene Lay, D.V.M., Founder and CEO
ProductsAntibodies, ELISA Kits and Sets, Recombinant Proteins, Custom Assay Development, Buffers and Solutions
ParentRevvity
Websitebiolegend.com

BioLegend is a global developer and manufacturer of antibodies and reagents used in biomedical research located in San Diego, California.[1] It was incorporated in June 2002 and has since expanded to include BioLegend Japan KK, where it is partnered with Tomy Digital Biology Co., Ltd. in Tokyo, BioLegend Europe in the United Kingdom, BioLegend GmbH in Germany, and BioLegend UK Ltd in the United Kingdom. In July 2021, BioLegend was acquired by PerkinElmer for $5.25 billion and now operates as Revvity.[2] BioLegend manufactures products in the areas of neuroscience, cell immunophenotyping, cytokines and chemokines, adhesion, cancer research, T regulatory cells, stem cells, innate immunity, cell-cycle analysis, apoptosis, and modification-specific antibodies. Reagents are created for use in flow cytometry, proteogenomics, ELISA, immunoprecipitation, Western blotting, immunofluorescence microscopy, immunohistochemistry, and in vitro or in vivo functional assays.[3]

History

BioLegend was founded by CEO, Gene Lay, D.V.M., who was also the co-founder of PharMingen. In 2011, BioLegend co-developed and introduced Brilliant Violet(TM)-conjugated antibodies, using a novel fluorophore based on Nobel Prize-winning chemistry developed by Sirigen.[4] In 2018, BioLegend introduced TotalSeq™ antibody-oligonucleotide conjugates for use in single cell proteogenomics analysis. BioLegend continued expansion and moved into a new 8-acre campus at BioLegend Way in 2019 with state of the art facilities designed to accommodate up to 1000 employees.

References

  1. ^ "Antibodies and conjugates for biomedical research: News from Cambridge BioScience". Archived from the original on 2011-07-18. Retrieved 2009-07-21.
  2. ^ "PerkinElmer to Acquire Antibody and Reagent Leader BioLegend". BioSpace. 26 July 2021. Archived from the original on 20 March 2024. Retrieved 20 March 2024.
  3. ^ "PerkinElmer and BioLegend Announce Custom Immunoassay Development Collaboration for Drug Discovery Research". Archived from the original on 2012-03-13. Retrieved 2009-07-21.
  4. ^ "BioLegend Company Profile". Archived from the original on 2017-04-25. Retrieved 2009-07-21.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.